Drug news
Lurasidone (Takeda) filed at EMA for Schizophrenia
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application (MAA) from Takeda for the oral atypical antipsychotic, lurasidone hydrochloride, for the treatment of Schizophrenia. This drug was developed by Dainippon Sumitomo and licensed to Takeda in March 2011, granting the latter exclusive commercialisation rights for lurasidone in 26 EU member states (excluding the UK), and Switzerland, Norway, Turkey and Russia. The drug is approved by the FDA as Latuda for treatment of Schizophrenia
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.